Daily Business Digest
Daily Business Digest
Loading date…
YOUR DAILY DOSE OF BUSINESS INTELLIGENCE

Hemas Holdings PLC Reports Strong Q2 FY27 Recovery, Eyes East African Expansion

COLOMBO, Sri Lanka – 05 November 2026 – Hemas Holdings PLC (CSE: HHL) has announced a significant rebound in its financial performance for the second quarter ended 30th September 2026, marking a clear recovery from a challenging first quarter. The diversified conglomerate reported a 17.0% year-on-year (YoY) increase in Q2 FY27 revenue, reaching LKR 37.8 billion, contributing to a half-year (H1 FY27) revenue of LKR 66.6 billion, up 9.5% YoY.

Q2 FY27 Performance Highlights Resilience and Strategic Growth

The interim financial statements reveal a sharp recovery in EBITDA, which nearly doubled to LKR 4.5 billion compared to Q1, driving a more than twofold increase in Group Earnings to LKR 2.0 billion. Despite absorbing much of the higher input, energy, and currency costs stemming from the Middle East war, disciplined cost management played a crucial role in supporting profitability during the quarter.

Group CEO Ashish Chandra highlighted the company’s approach to cost pressures, stating, “We chose to absorb much of the higher input, energy and currency costs arising from the Middle East war rather than pass the full burden on to consumers, while disciplined cost management supported profitability during the quarter.” He further noted that nearly half of the Group’s revenue is derived from businesses with regulated pricing, limiting the ability to fully offset cost increases through price adjustments. For the consumer business, judicious pricing corrections were implemented to safeguard volume growth, leveraging technology and innovation to lower the cost base.

Key Financial and Operational Metrics

The second quarter saw all four sectors contributing to growth, with Hospitals leading with a 19.3% increase and Consumer Brands following closely with an 18.3% rise. Group revenue for Q2 FY27 rose 31.4% quarter-on-quarter (QoQ), with EBITDA margin improving by 4.1 percentage points QoQ to 11.9%.

For the first half of FY27, revenue grew 9.5% YoY to LKR 66.6 billion, with the strong second quarter delivering approximately two-thirds of H1 earnings. While overall Group Earnings declined 9.7% to LKR 2.9 billion for H1, primarily due to the weaker first quarter, the Q2 performance indicates a strong turnaround.

Sectoral Performance Overview:

  • Consumer Brands: Revenue increased by 18.3% YoY to LKR 15.57 billion in Q2, with Beauty, Home Care, and Baby Care categories achieving double-digit growth. The acquisition of Twiga Stationers & Printers Limited in Kenya is a significant strategic move.
  • Life Sciences: Revenue grew 16.2% YoY to LKR 18.36 billion. Hemas Pharmaceuticals maintained market leadership, securing six new product registrations. Pharmaceutical manufacturing saw 11% YoY growth, driven by volumes.
  • Hospitals: Demonstrated strong performance with 19.3% YoY revenue growth to LKR 3.20 billion, the highest within the Group. Admissions grew 4.4% during the quarter, and five new diagnostic centres were added.
  • Mobility: Revenue increased 3.7% YoY to LKR 646 million, supported by elevated freight rates and a strategic shift towards higher-yield shipments, despite temporary route suspensions due to the Middle East conflict.

Strategic Milestones and Future Outlook

A significant strategic development during the quarter was the Group’s first international acquisition on 17th August 2026. Hemas, through its subsidiary Atlas Axillia, acquired a 75% stake in Twiga Stationers & Printers Limited, a leading stationery manufacturer and exporter in East Africa. This acquisition strengthens Hemas’ position as a learning solutions provider and establishes a platform for long-term growth across the region.

Economically, the quarter presented a mixed picture, with average inflation rising to 7.7% and the LKR appreciating 1.7% against the USD, though remaining 5.0% weaker year-to-date. Brent crude prices fluctuated, impacting local fuel costs.

Looking ahead, Hemas’ Long Range Plan (LRP) sets ambitious targets of mid-teen compound annual growth in both revenue and earnings, with 15% of revenue expected from international markets by FY30. The Group has earmarked over USD 100 million for new growth platforms.

Chandra concluded, “Q2 FY27 demonstrated the resilience of Hemas in a challenging environment… With a clear strategy, trusted brands and talented people, we are determined to convert this quarter’s recovery into sustained growth and lasting value for our shareholders, consumers and the communities we serve.”

Source: Read original document


Daily Stock Market Update

Weekly Tea Market Update

Vegetable Market

Weekly Economic Update


Latest Updates